CapsoVision Inc (CV)

NASD · Healthcare · Medical Devices · USA

CapsoVision Inc is a small cap company (market value between $300 million and $2 billion) in the Medical Devices industry.

CapsoVision develops diagnostic products for identifying gastrointestinal tract abnormalities using advanced imaging and artificial intelligence technology. The company's primary offering is the CapsoCam Plus capsule endoscopy system for small bowel visualization, supported by CapsoCloud and CapsoView software. CapsoVision sells to gastroenterologists in clinics and hospitals throughout the U.S. and internationally.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the CapsoVision Inc stock.

Our verdict on CV

Not valued: We cannot value this company yet.

We do not publish a value for this company: its filings cover two fiscal years and projecting growth needs four in a row.

ETFs with the most weight in CV

8 more funds hold it; the full list is part of the paid plan.

Browse

Peers in Medical Devices

All 140 Medical Devices stocks

Cheaper than CV in Medical Devices

61 more in this industry show a wider margin of safety.

Is CV undervalued or overvalued?

We do not publish a verdict on CV yet. A discounted cash flow projects five years of revenue, so it needs this company’s own growth history: four consecutive fiscal years of accounts, which give three year-on-year growth rates. Its filings on our archive cover two fiscal years so far; the next annual report should close the gap. We could plug in a generic rate, but that would be a valuation of an average company, not of this one.

What is the intrinsic value of CV?

We do not publish one (as of the 2026-11-17 close). A discounted cash flow projects five years of revenue, so it needs this company’s own growth history: four consecutive fiscal years of accounts, which give three year-on-year growth rates. Its filings on our archive cover two fiscal years so far; the next annual report should close the gap. We could plug in a generic rate, but that would be a valuation of an average company, not of this one.